Sleep disorders associated with montelukast in children with respiratory allergy
Main Article Content
Keywords
Asthma, Rhinitis, Sleep Disorders, Leukotriene Antagonists
Abstract
Abstract
Background: Asthma and allergic rhinitis are the most common respiratory allergic disorders in the Mexican population. Montelukast is a leukotriene receptor antagonist that has been widely used in these conditions. An association has been documented with the onset and modification of multiple sleep disorders, as well as other neuropsychiatric alterations in pediatric population.
Objective: To analyze the association between montelukast and sleep disorders in children with respiratory allergies.
Material and methods: A prospective and analytical cohort study was conducted. Patients aged 5 to 17 years diagnosed with asthma and allergic rhinitis were recruited from a third-level hospital. They were divided into 2 groups: a montelukast user group and a control group. Patients who withdrew their consent or did not complete the questionnaires were excluded.
Results: 120 children were analyzed, 60 children using montelukast and 60 not using it. The median age was 9 and 10 years, respectively. Five (4.17%) of the children had asthma as their primary diagnosis, 60 (50%) had allergic rhinitis, and 55 (45.83%) had both asthma and allergic rhinitis. Among the children taking montelukast, 46 (73.02%) had sleep disorders, compared to 17 (14.17%) of those not taking montelukast. The association showed an odds ratio (OR) of 8.31, p < 0.0001.
Conclusion: Montelukast use was associated with the presence of sleep disorders in the studied population.
References
1. Deng SZ, Jalaludin BB, Antó JM, et al. Climate change, air pollution, and allergic respiratory diseases: A call to action for health professionals. Chinese Medical Journal. 2020:133(13);1552-60. doi: 10.1097/CM9.0000000000000861
2. Escarrer-Jaume M, Juliá-Benito JC, Quevedo-Teruel S, et al. Changes in epidemiology and clinical practice in IgE-mediated Allergy in children. An Pediatr (Engl Ed). 2021;95(1):56.e1-8. doi: 10.1016/j.anpede.2021.04.002
3. Calle A, Santamaría L, Sánchez J, et al. The current state of the knowledge about local allergic rhinitis. Rev Alerg Mex. 2020;67(1):54-61. doi. 10.29262/ram.v67i1.522
4. Naclerio R, Ansotegui IJ, Bousquet J, et al. International expert consensus on the management of allergic rhinitis (AR) aggravated by air pollutants: Impact of air pollution on patients with AR: Current knowledge and future strategies. World Allergy Organ J. 2020;13(3):100106. doi: 10.1016/j.waojou.2020.100106
5. Meng Y, Wang C, Zhang L. Advances and novel developments in allergic rhinitis. Allergy. 2020;75(12):3069-76. doi: 10.1111/all.14586
6. Global Iniciative for Asthma. Global Strategy for Asthma Management and Prevention, 2025. Updated 15 November 2025. Disponible en: https://ginasthma.org/2025-gina-strategy-report/
7. Reyes-Baque J, Cajape-González A, Jaramillo-Baque Y, et al. Características clínicas y epidemiológicas del asma bronquial en niños. Revista Científica Dominio de las Ciencias. 2021;7(2):1371-90. Disponible en: http://dominiodelasciencias.com/ojs/index.php/es/index
8. Plaza Moral V, Alobid I, Álvarez Rodríguez C, et al. GEMA 5.3. Spanish Guideline on the Management of Asthma. Open Respir Arch. 2023;5(4):100277. doi: 10.1016/j.opresp.2023.100277
9. Bian S, Li L, Wang Z, et al. Neuropsychiatric side reactions of leukotriene receptor antagonist, antihistamine, and inhaled corticosteroid: A real-world analysis of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). World Allergy Organization Journal. 2021;14(10). doi: 10.1016/j.waojou.2021.100594
10. Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. Int Forum Allergy Rhinol. 2023;13(4):293-859. doi: 10.1002/alr.23090
11. Toral Pérez M, Moral Gil L, Bosque García M. Farmacoterapia de las enfermedades alérgicas. AEP Protocolos. 2019;35-49. Disponible en: https://static.aeped.es/03_farmacoterapia_alergia_0fb591e494.pdf
12. Caudevilla Lafuente P, García Íñiguez JP, Martín de Vicente C. Reacciones adversas a montelukast: de la teoría a la práctica. Serie de casos. Arch Argent Pediatr. 2021;119(4):e357-9. doi: 10.5546/aap.2021.e357
13. Park JS, Cho YJ, Yun JY, et al. Korean childhood Asthma REsearch (KARE) team. Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series. Eur Respir J. 2022;60(5):2102467. doi: 10.1183/13993003.02467-2021
14. Shin EY, Jin JH, Kang MK, et al. Adverse drug reactions of montelukast and pranlukast: Analysis of the Korea database. Asian Pac J Allergy Immunol. 2024;42(4):382-94. doi: 10.12932/AP-030821-1202
15. Mayoral K, Lizano-Barrantes C, Zamora V, et al. Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis. European Respiratory Review. 2023;32(170). doi: 10.1183/16000617.0124-2023
16. Lo CWH, Pathadka S, Qin SX, et al. Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review. Eur Respir Rev. 2023;32(169):230079. doi: 10.1183/16000617.0079-2023
17. Ángeles-Garay U, Becerril-Ángeles MH, Morán-Sotelo D, et al. Control del asma y calidad de vida en niños asmáticos y sus cuidadores. Rev Med Inst Mex Seguro Soc. 2020;58(5):548-56. doi: 10.24875/RMIMSS.M20000084
18. Cohen Y, Reiter J, Gileles-Hillel A. Sleep-related disorders in children: A narrative review. Pediatr Discovery. 2024;2(2):e76. doi: 10.1002/pdi3.76
19. Navarro Vergara A, González Rabelino G. Trastornos del sueño y su impacto en el neurodesarrolo. Medicina (B Aires). 2022;82 (Suppl III):30-34. Disponible en: https://www.scielo.org.ar/pdf/medba/v82s3/1669-9106-medba-82-s3-30.pdf
20. Watson S, Kaminsky E, Taavola H, et al. Montelukast and Nightmares: Further Characterisation Using Data from VigiBase. Drug Saf. 2022;45(6):675-84. doi: 10.1007/s40264-022-01183-2
21. Martínez Cayuelas L, March-Villalba JA, Valencia Guadalajara V, et al. Evaluation of sleep hygiene and prevalence of sleep disorders in patients with monosymptomatic enuresis. Usefulness of the BEARS sleep screening tool. Actas Urol Esp (Engl Ed). 2020 Sep;44(7):477-82. English, Spanish. doi: 10.1016/j.acuro.2020.05.005
22. Romeo DM, Cordaro G, Macchione E, et al. Application of the Sleep Disturbance Scale for Children (SDSC) in infants and toddlers. Sleep Med. 2021;81:62-8. doi: 10.1016/j.sleep.2021.02.001
23. Altaş U, Söğütlü Y, Altaş ZM, et al. Seasonal pattern of emergency department visits by children with asthma. East Mediterr Health J. 2023;29(10):789-95. doi: 10.26719/emhj.23.114
24. Tunca S, Yilmaz O, Ocalan M, et al. Potentially Overlooked Risk for Neuropsychiatric Symptoms in Children: Montelukast Treatment. J Paediatr Child Health. 2025;61(8):1287-94. doi: 10.1111/jpc.70092
25. Benard B, Bastien V, Vinet B, et al. Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice. Eur Respir J. 2017;50(2):1700148. doi: 10.1183/13993003.00148-2017
26. Yilmaz O, Turktas I, Ilbilge H, et al. Neuropsychiatric adverse drug reactions induced by montelukast in children with asthma impair the quality of life. Journal of Asthma. 2022;59(3):580-9. doi: 10.1080/02770903.2020.1861626
27. Paljarvi T, Forton J, Luciano S, et al. Analysis of Neuropsychiatric Diagnoses After Montelukast Initiation. JAMA Netw Open. 2022;5(5):e2213643. doi: 10.1001/jamanetworkopen.2022.13643
28. García-Ramírez UN, Navarrete-Rodríguez EM, Chávez-García AA, et al. Guía práctica de seguimiento y manejo del paciente con asma grave tratado con biológicos. Rev Med Inst Mex Seguro Soc. 2022;60(2):201-210. Available from: https://revistamedica.imss.gob.mx/index.php/revista_medica/article/view/4273
29. Gemke RJBJ, Burger P, Steur LMH. Sleep disorders in children: classification, evaluation, and management. A review. Eur J Pediatr. 2025 Jan 1;184(1):39-. doi:10.1007/S00431-024-05822-X/METRICS PubMed PMID: 39579198.
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.